WINTON GROUP Ltd Sells 270,739 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

WINTON GROUP Ltd decreased its position in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 87.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,241 shares of the biopharmaceutical company’s stock after selling 270,739 shares during the quarter. WINTON GROUP Ltd owned about 0.08% of Puma Biotechnology worth $117,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Prudential Financial Inc. increased its position in Puma Biotechnology by 5.8% during the fourth quarter. Prudential Financial Inc. now owns 106,285 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 5,800 shares during the period. LPL Financial LLC increased its holdings in shares of Puma Biotechnology by 23.6% during the fourth quarter. LPL Financial LLC now owns 26,567 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 5,080 shares during the period. Sei Investments Co. raised its position in shares of Puma Biotechnology by 8.0% in the fourth quarter. Sei Investments Co. now owns 311,661 shares of the biopharmaceutical company’s stock valued at $951,000 after buying an additional 23,179 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Puma Biotechnology by 8.4% in the fourth quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company’s stock valued at $2,893,000 after buying an additional 73,833 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Puma Biotechnology by 32.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 487,368 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 118,913 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PBYI. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 8th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, February 28th.

Insider Activity at Puma Biotechnology

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares of the company’s stock, valued at $343,195.65. This represents a 7.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. The trade was a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 23.70% of the stock is owned by insiders.

Puma Biotechnology Trading Down 5.7 %

Shares of PBYI stock opened at $2.96 on Tuesday. Puma Biotechnology, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $6.06. The stock’s fifty day moving average price is $3.10 and its two-hundred day moving average price is $2.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The company has a market cap of $146.85 million, a PE ratio of 6.17 and a beta of 1.33.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. The firm had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. Equities analysts predict that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.